JP6784668B2 - 相乗的オーリスタチン組合せ - Google Patents

相乗的オーリスタチン組合せ Download PDF

Info

Publication number: JP6784668B2
Authority: JP; Japan
Prior art keywords: auristatin; pharmaceutically acceptable; cancer; pi3k; adc
Prior art date: 2014-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2017518541A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017530983A (ja

JP2017530983A5 (2

Inventor

サプラプヤ

ショアボリス

Original Assignee

ファイザー・インク

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-10

Filing date

2015-09-29

Publication date

2020-11-11

2015-09-29 Application filed by ファイザー・インク filed Critical ファイザー・インク

2017-10-19 Publication of JP2017530983A publication Critical patent/JP2017530983A/ja

2018-11-08 Publication of JP2017530983A5 publication Critical patent/JP2017530983A5/ja

2020-11-11 Application granted granted Critical

2020-11-11 Publication of JP6784668B2 publication Critical patent/JP6784668B2/ja

Status Active legal-status Critical Current

2035-09-29 Anticipated expiration legal-status Critical

Links

PJMPHFMQSWEISQ-ZEXWDMEUSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](C)[C@H](c1ccccc1)O)=O)OC)=O)OC)N(C)C(/C(/C(C)C)=[I]\NC(C(C)(C)N)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](C)[C@H](c1ccccc1)O)=O)OC)=O)OC)N(C)C(/C(/C(C)C)=[I]\NC(C(C)(C)N)=O)=O PJMPHFMQSWEISQ-ZEXWDMEUSA-N 0.000 description 1
DWZAEMINVBZMHQ-UHFFFAOYSA-N CN(C)C(CC1)CCN1C(c(cc1)ccc1NC(Nc(cc1)ccc1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1)=O)=O Chemical compound CN(C)C(CC1)CCN1C(c(cc1)ccc1NC(Nc(cc1)ccc1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1)=O)=O DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP2017518541A 2014-10-10 2015-09-29 相乗的オーリスタチン組合せ Active JP6784668B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462062192P	2014-10-10	2014-10-10
US62/062,192		2014-10-10
PCT/IB2015/057457 WO2016055907A1 (en)	2014-10-10	2015-09-29	Synergistic auristatin combinations

Publications (3)

Publication Number	Publication Date
JP2017530983A JP2017530983A (ja)	2017-10-19
JP2017530983A5 JP2017530983A5 (2)	2018-11-08
JP6784668B2 true JP6784668B2 (ja)	2020-11-11

Family

ID=54288858

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017518541A Active JP6784668B2 (ja)	2014-10-10	2015-09-29	相乗的オーリスタチン組合せ

Country Status (12)

Country	Link
US (1)	US10617670B2 (2)
EP (2)	EP3549583A1 (2)
JP (1)	JP6784668B2 (2)
KR (1)	KR20170058432A (2)
CN (1)	CN107106685A (2)
AU (1)	AU2015329625B2 (2)
BR (1)	BR112017006113A8 (2)
CA (1)	CA2907878A1 (2)
IL (1)	IL251619B (2)
MX (1)	MX2017004580A (2)
RU (1)	RU2717570C2 (2)
WO (1)	WO2016055907A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3019559A4 (en)	2013-08-22	2017-04-05	Sony Corporation	Water soluble fluorescent or colored dyes and methods for their use
AU2017240154B2 (en)	2016-04-01	2021-08-12	Sony Group Corporation	Ultra bright dimeric or polymeric dyes
US9851359B2 (en)	2016-04-06	2017-12-26	Sony Corporation Of America	Ultra bright dimeric or polymeric dyes with spacing linker groups
KR102526802B1 (ko)	2016-05-11	2023-05-02	소니그룹주식회사	초고명도 이량체성 또는 중합체성 염료
JP7312929B2 (ja)	2016-07-29	2023-07-24	ソニーグループ株式会社	超明色二量体またはポリマー色素およびその調製のための方法
CN111093711A (zh)	2017-10-05	2020-05-01	索尼公司	可编程的树枝状药物
JP7551056B2 (ja)	2017-10-05	2024-09-17	ソニーグループ株式会社	プログラマブルなポリマー薬物
WO2019088176A1 (ja) *	2017-10-31	2019-05-09	国立大学法人神戸大学	抗体薬物複合体効果増強剤
CN111836645A (zh)	2017-11-16	2020-10-27	索尼公司	可编程的聚合药物
CN111712511B (zh) *	2017-11-30	2024-07-16	拉德克斯公司	澳瑞他汀e衍生物的白蛋白结合产物
EP3737419B1 (en)	2018-01-12	2024-04-10	Sony Group Corporation	Phosphoalkyl polymers comprising biologically active compounds
US12194104B2 (en)	2018-01-12	2025-01-14	Sony Group Corporation	Phosphoalkyl ribose polymers comprising biologically active compounds
CN111565756A (zh)	2018-01-12	2020-08-21	索尼公司	包含生物活性化合物的具有刚性间隔基团的聚合物
US11874280B2 (en)	2018-03-19	2024-01-16	Sony Group Corporation	Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko)	2018-03-21	2025-09-26	소니그룹주식회사	링커 군을 갖는 중합체성 텐덤 염료
US12006438B2 (en)	2018-06-27	2024-06-11	Sony Group Corporation	Polymeric dyes with linker groups comprising deoxyribose
EP3820944A1 (en)	2018-07-13	2021-05-19	Sony Corporation	Polymeric dyes having a backbone comprising organophosphate units
WO2021062176A2 (en)	2019-09-26	2021-04-01	Sony Corporation	Polymeric tandem dyes with linker groups
EP4038081A1 (en)	2019-09-30	2022-08-10	Sony Group Corporation	Nucleotide probes
JP7556194B2 (ja) *	2019-12-13	2024-09-26	Ｔｏｐｐａｎホールディングス株式会社	細胞構造体及びその使用
WO2022125564A1 (en)	2020-12-07	2022-06-16	Sony Group Corporation	Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7696231B2 (en)	2001-10-30	2010-04-13	Laboratoires Serono Sa	Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs)
US7196090B2 (en)	2002-07-25	2007-03-27	Warner-Lambert Company	Kinase inhibitors
US7498298B2 (en) *	2003-11-06	2009-03-03	Seattle Genetics, Inc.	Monomethylvaline compounds capable of conjugation to ligands
US20090304721A1 (en) *	2005-09-07	2009-12-10	Medlmmune, Inc	Toxin conjugated eph receptor antibodies
EP2041676A4 (en)	2006-06-26	2012-05-16	Nielsen Co Us Llc	METHOD AND DEVICES FOR IMPROVING THE DATA WAREHOUSE EFFICIENCY
DK2074122T5 (da)	2006-09-15	2014-03-17	Pfizer Prod Inc	Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
EP2144628B1 (en) *	2007-05-08	2012-10-17	Genentech, Inc.	Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CA2701155C (en)	2007-10-02	2016-11-22	Chugai Seiyaku Kabushiki Kaisha	Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
AP2775A (en)	2008-05-23	2013-09-30	Wyeth Llc	Triazine compounds as P13 kinase and MTOR inhibitors
BR112012030311A2 (pt) *	2010-06-08	2017-01-24	Genentech Inc	anticorpo
AU2011316917B2 (en) *	2010-10-22	2016-02-25	Seagen Inc.	Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
DK2694111T3 (en)	2011-04-01	2016-10-10	Wyeth Llc	Antibody pharmaceutical conjugates
PE20142312A1 (es) *	2011-10-28	2015-01-25	Genentech Inc	Combinaciones terapeuticas y metodos para tratar el melanoma
MY168297A (en) *	2011-11-17	2018-10-23	Pfizer	Cytotoxic Peptides and Antibody Drug Conjugates Thereof
HK1214282A1 (zh) *	2012-11-07	2016-07-22	辉瑞公司	抗-notch3抗体及抗体-药物缀合物
US9777070B2 (en) *	2014-04-30	2017-10-03	Pfizer Inc	Anti-PTK7 antibody-drug conjugates

2015
- 2015-09-29 MX MX2017004580A patent/MX2017004580A/es unknown
- 2015-09-29 JP JP2017518541A patent/JP6784668B2/ja active Active
- 2015-09-29 WO PCT/IB2015/057457 patent/WO2016055907A1/en not_active Ceased
- 2015-09-29 BR BR112017006113A patent/BR112017006113A8/pt not_active Application Discontinuation
- 2015-09-29 EP EP19170411.3A patent/EP3549583A1/en not_active Withdrawn
- 2015-09-29 AU AU2015329625A patent/AU2015329625B2/en not_active Ceased
- 2015-09-29 RU RU2017112048A patent/RU2717570C2/ru active
- 2015-09-29 KR KR1020177010980A patent/KR20170058432A/ko not_active Ceased
- 2015-09-29 US US15/516,780 patent/US10617670B2/en active Active
- 2015-09-29 CN CN201580054253.XA patent/CN107106685A/zh active Pending
- 2015-09-29 EP EP15778051.1A patent/EP3204005A1/en not_active Withdrawn
- 2015-10-07 CA CA2907878A patent/CA2907878A1/en active Pending
2017
- 2017-04-06 IL IL251619A patent/IL251619B/en active IP Right Grant

Also Published As

Publication number	Publication date
BR112017006113A2 (pt)	2017-12-19
JP2017530983A (ja)	2017-10-19
EP3204005A1 (en)	2017-08-16
EP3549583A1 (en)	2019-10-09
RU2017112048A (ru)	2018-11-15
CN107106685A (zh)	2017-08-29
RU2717570C2 (ru)	2020-03-24
AU2015329625A1 (en)	2017-04-13
WO2016055907A1 (en)	2016-04-14
RU2017112048A3 (2)	2019-05-07
KR20170058432A (ko)	2017-05-26
US10617670B2 (en)	2020-04-14
BR112017006113A8 (pt)	2018-04-24
IL251619A0 (en)	2017-06-29
AU2015329625B2 (en)	2018-04-05
CA2907878A1 (en)	2016-04-10
MX2017004580A (es)	2017-06-27
US20180228769A1 (en)	2018-08-16
IL251619B (en)	2020-10-29

Legal Events

Date	Code	Title	Description
2018-09-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180925
2018-09-25	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180925
2019-07-23	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190723
2019-10-11	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191011
2019-10-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191028
2020-01-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200106
2020-03-11	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200311
2020-05-21	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200521
2020-09-28	TRDD	Decision of grant or rejection written
2020-10-20	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201020
2020-10-27	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201023
2020-10-27	R150	Certificate of patent or registration of utility model	Ref document number: 6784668 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2023-10-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-10-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-10-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6784668B2 (ja)	2020-11-11	相乗的オーリスタチン組合せ
JP7793556B2 (ja)	2026-01-05	抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ
JP2024161445A (ja)	2024-11-19	抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN108024540B (zh)	2021-09-17	用于治疗癌症的方法
JP2025041725A (ja)	2025-03-26	抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
JP2023539715A (ja)	2023-09-19	抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
KR20120115237A (ko)	2012-10-17	암 치료 방법 및 조성물
CN118450908A (zh)	2024-08-06	抗体-药物缀合物和atr抑制剂的组合
KR20140025434A (ko)	2014-03-04	Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
JP2023502929A (ja)	2023-01-26	Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法
JP2017503842A (ja)	2017-02-02	癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP2017536356A (ja)	2017-12-07	肺の非小細胞癌及び多形性膠芽腫を処置するための放射線療法と一緒のジアンヒドロガラクチトール
MX2014010591A (es)	2014-09-18	Terapia combinada para el tratamiento de cancer de ovario.
AU2019201169A1 (en)	2019-03-07	Pim kinase inhibitor combinations
CA2902144A1 (en)	2014-10-09	Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
CN110996960A (zh)	2020-04-10	第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合
CN114302745A (zh)	2022-04-08	包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
KR20220008870A (ko)	2022-01-21	노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
Swami et al.	2014	Marine sponge derived eribulin in preclinical and clinical studies for cancer
HK1242995A1 (en)	2018-07-06	Synergistic auristatin combinations
WO2025049904A1 (en)	2025-03-06	Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
EA049478B1 (ru)	2025-03-28	Комбинация конъюгата антитела и лекарственного средства и ингибитора atr
HK40054690A (en)	2022-02-25	Combination of antibody-drug conjugate and kinase inhibitor
Molife et al.	2011	1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours